Inhibikase Therapeutics Inc (IKT) stock surged over 30% on Wednesday after the company announced a $110 million private placement financing. The funds will support a Phase 2b trial for pulmonary arterial hypertension (PAH) and general corporate needs. The deal involves the sale of common stock, pre-funded warrants, and accompanying Series A-1 and B-1 warrants, with new board members joining and existing ones resigning. The placement is expected to close on October 21.